14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
BNTX vs REGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over BioNTech SE American Depositary Share (BNTX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BNTX carries a Unified Composite Score of 43.3/100 (HOLD) at $81.38 (7.0x Forward P/E, -55.5% operating margin), whereas REGN carries 45.1/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin).
Technical & Structure Timing Caution: BNTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7); meanwhile REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BNTX vs REGN. Trailing 12-month operating profitability (BNTX -55.5% vs REGN 30.4%) and valuation multiples (BNTX 7.0x vs REGN 14.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $20.6B market capitalization and -55.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
REGN Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment16.3% of Rev ($2.75B)
90D Engineering Disclosures0 Published
Investor FAQ BNTX vs REGN Key Questions & Quantitative Answers
As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over BioNTech SE American Depositary Share (BNTX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BNTX carries a Unified Composite Score of 43.3/100 (HOLD) at $81.38 (7.0x Forward P/E, -55.5% operating margin), whereas REGN carries 45.1/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin). Technical & Structure Timing Caution: BNTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7); meanwhile REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
REGN leads the Growth & Scale pillar: BNTX posts -15.1% YoY revenue growth and -43.2% YoY earnings growth on $2.42B TTM revenue (76.7% gross margin, -55.5% operating margin), compared with REGN at +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin). On trailing 12-month operating scale, BNTX generates $2.42B in USD-normalized revenue versus $16.9B for REGN. In operating R&D and SG&A reinvestment, BNTX deploys N/A (0 90-day corporate R&D disclosures) versus 16.3% of Rev ($2.75B) (0 disclosures) for REGN.
BNTX screens cheaper on headline valuation multiples. BNTX trades at 7.0x Forward P/E, 7.0x Trailing P/E, 0.05x PEG, and 8.5x EV/Revenue (-42.0% EBITDA margin), whereas REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BNTX (-8.1% ROE) versus REGN (14.9% ROE) capital efficiency.
In options market volatility and institutional positioning, BNTX carries 41.9% implied volatility (76th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 31% Vol realized risk). By comparison, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.